“…Compared to the Western population, BCs have diverse clinical, pathological and molecular features including early onset, higher tumor grade, higher human epidermal growth factor receptor (HER)2 amplification rate, more aggressive subtypes and a lower rate of luminal subtype, in the GCC population ( 7 – 9 ). Evidence suggests that approximately 46.2% to 54% of BC patients are diagnosed at advanced disease stage ( 7 , 8 , 10 – 12 ), 23.3% to 28% are diagnosed with localized tumors while ≤2% with in-situ carcinoma ( 8 , 10 ). In the GCC region, the vast majority of BC cases (82.1% to 93%) have invasive ductal carcinoma (IDC) ( 7 , 8 ), and 19.2% to 29.5% have HER2 overexpression ( 7 , 8 , 12 ), while 14.3% to 26.9% have triple-negative BC (TNBC) ( 7 , 8 ).…”